EMEA-001349-PIP01-12-M03

Key facts

Active substance
daclizumab
Therapeutic area
Neurology
Decision number
P/0005/2020
PIP number
EMEA-001349-PIP01-12-M03
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of multiple sclerosis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Biogen Idec Ltd

E-mail: pip.enquiries@biogen.com
Tel. +44 (0)1628 501014

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating